Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo
This article was originally published in The Gray Sheet
Executive SummaryFollowing simultaneous and swift FDA approvals, Abbott Molecular Diagnostics is launching its Vysis ALK molecular test to identify the small percentage of non-small-cell lung cancer patients who would respond to Pfizer’s Xalkori (crizotinib) cancer drug.
You may also be interested in...
Siemens teams with Pfizer on companion Dx. XLumena gains pancreatic stent approval. AtriCure acquires Estech. More news.